Literature DB >> 25312733

Adverse effects of statins - myths and reality.

Iveta Šimić, Željko Reiner1.   

Abstract

Statins reduce cardiovascular mortality and morbidity as well as cardiovascular events in patients with a very high risk of cardiovascular disease (CVD) and also in subjects with high or moderate risk by reducing the levels of low-density lipoprotein cholesterol (LDL-C). Although they are considered to be drugs with a very good safety profile, because of their wide use there are many concerns that their adverse effects might compromise their proven beneficial effects. Therefore this article reviews all the data and provides an evidence- based insight what are the proven adverse effects of statins and what are the "myths" about them. The most important side effects include myopathy and rhabdomyolysis. Another side effect is increased activity of liver tests which occurs occasionally and is reversible. However, recent studies even suggest that statin therapy can improve hepatic steatosis. It is beyond any doubt that statins do slightly increase the incidence of type 2 diabetes mellitus in people with two or more components of metabolic syndrome but the cardiovascular benefits of such a treatment by far exceed this risk. Statin therapy has also been associated with some adverse renal effects, eg. acute renal failure, but recent data suggest even a possible protective effect of these drugs on renal dysfunction. Concerns that statins might increase cancer have not been proven. On the contrary, several studies have indicated a possible benefit of these drugs in patients with different types of cancer. Early concerns about cognitive dysfunction and memory loss associated with statins use could not be proven and most recent data even suggest a possible beneficial effect of statins in the prevention of dementia. Systematic reviews and clinical guidelines suggest that the cardiovascular benefits of statins by far out-weight non-cardiovascular harms in patients with cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25312733     DOI: 10.2174/1381612820666141013134447

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  36 in total

Review 1.  Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Authors:  Annalisa Marcuzzi; Elisa Piscianz; Claudia Loganes; Liza Vecchi Brumatti; Alessandra Knowles; Sabrine Bilel; Alberto Tommasini; Roberta Bortul; Marina Zweyer
Journal:  Int J Mol Sci       Date:  2015-12-30       Impact factor: 5.923

2.  Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial.

Authors:  Wan-Yong Yang; Yu-Feng Li; Zi-Ran Wang; Tian-Xia Yu; Dong-Juan Xu; Nan Yang; Xiao-Yuan Niu; Xue-Li Cai; Wen-Yan Zhuo; Xue-Mei Wu; Min Yan; Jun-Shan Zhou; Hao-Wen Zhang; Zhi-Gang Liang; Wen-Jun Wu; Jian-Hua Cheng; Li-An Huang; Yu-Sheng Zhang; Ying Guan; Ze-Feng Tan; Dan Lu; Niu He; Da-Wei Dong; Hui-Li Zhu; Bing Yang; Qing-Yu Shen; An-Ding Xu
Journal:  J Neurol       Date:  2021-02-08       Impact factor: 4.849

Review 3.  Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Authors:  Natalie C Ward; Jing Pang; Jacqueline D M Ryan; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-01-24       Impact factor: 2.882

4.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

Review 5.  Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes.

Authors:  Anthony Paulo Sunjaya; Angela Felicia Sunjaya; Samuel Halim; Frans Ferdinal
Journal:  Int J Angiol       Date:  2016-02-18

Review 6.  Management of patients with familial hypercholesterolaemia.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 7.  Hypertriglyceridaemia and risk of coronary artery disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2017-03-16       Impact factor: 32.419

8.  Validation of Human Sterol 14α-Demethylase (CYP51) Druggability: Structure-Guided Design, Synthesis, and Evaluation of Stoichiometric, Functionally Irreversible Inhibitors.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Zdzislaw Wawrzak; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2019-11-11       Impact factor: 7.446

9.  Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Authors:  Fardin Nabizadeh; Mohammad Balabandian; Amir Mohammad Sharafi; Ali Ghaderi; Mohammad Reza Rostami; Abdorreza Naser Moghadasi
Journal:  Acta Neurol Belg       Date:  2021-07-28       Impact factor: 2.471

Review 10.  Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.

Authors:  Daniele Pastori; Arianna Pani; Arianna Di Rocco; Danilo Menichelli; Gianluca Gazzaniga; Alessio Farcomeni; Laura D'Erasmo; Francesco Angelico; Maria Del Ben; Francesco Baratta
Journal:  Br J Clin Pharmacol       Date:  2021-06-28       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.